Table 1.
Characteristics of patients who received reduced-intensity regimens
| Variable | Donor type | P | |
|---|---|---|---|
| Haplo PTCy/CNI/MMF | MUD PTCy/CNI/MMF | ||
| No. of patients | 1211 | 187 | |
| Median age (range), y | 62 (18-81) | 65 (20-80) | .01 |
| Age group | |||
| ≤55 | 371 (31) | 24 (13) | |
| >55 | 840 (69) | 163 (87) | |
| Race | <.0001 | ||
| White | 874 (72) | 177 (95) | |
| Other | 337 (28) | 10 (5) | |
| Sex | .42 | ||
| Male | 718 (56) | 105 (56) | |
| Female | 493 (41) | 82 (44) | |
| Performance score | .21 | ||
| 90-100 | 636 (53) | 111 (59) | |
| ≤80 | 549 (45) | 73 (39) | |
| Not reported | 26 (2) | 3 (2) | |
| Comorbidity score | .27 | ||
| ≤2 | 603 (50) | 85 (46) | |
| ≥3 | 608 (50) | 102 (54) | |
| Recipient CMV serostatus | .16 | ||
| Negative | 372 (31) | 70 (37) | |
| Positive | 837 (69) | 117 (63) | |
| Not reported | 2 (< 1) | — | |
| Disease | .77 | ||
| Acute myeloid leukemia | 724 (60) | 113 (60) | |
| Acute lymphoblastic leukemia | 212 (18) | 29 (16) | |
| Myelodysplastic syndrome | 275 (23) | 45 (24) | |
| Disease risk index | .07 | ||
| Low/intermediate risk | 954 (79) | 149 (80) | |
| High/very high risk | 224 (18) | 36 (19) | |
| Not reported | 33 (3) | 2 (1) | |
| Interval from diagnosis to HCT, median ( IQR ), mo | |||
| Low/intermediate risk | 6 (4-10) | 6 (4-9) | .87 |
| High/very high risk | 9 (5-19) | 8 (5-11) | .08 |
| Conditioning regimen | <.0001 | ||
| TBI | 1140 (94) | 88 (47) | |
| TBI/fludarabine/cyclophosphamide | 1040 | 70 | |
| TBI/fludarabine | 29 | 6 | |
| TBI/melphalan | 71 | 12 | |
| Non-TBI | 71 (6) | 99 (53) | |
| Fludarabine/busulfan | 12 | 38 | |
| Fludarabine/melphalan | 59 | 61 | |
| Graft type | <.0001 | ||
| Bone marrow | 535 (44) | 30 (16) | |
| Peripheral blood | 676 (56) | 157 (84) | |
| Transplant period | .01 | ||
| 2011-2014 | 256 (21) | 25 (13) | |
| 2015-2018 | 955 (79) | 162 (87) | |
Data are no. of patients (percentage of study group), unless otherwise stated.
IQR, interquartile range.